• Home  
  • Lilly Breaks Ground on $3.5 Billion Manufacturing Facility in Pennsylvania
- News

Lilly Breaks Ground on $3.5 Billion Manufacturing Facility in Pennsylvania

One of four sites announced by Lilly for manufacturing injectable medicines and devices, the Lehigh Valley facility will support the production of obesity treatments, including retatrutide. It is expected to become operational by 2031.

Lilly to Boost Obesity Drug Production with New Pennsylvania Facility

Image source: Eli Lilly and Company

Eli Lilly and Company has broken ground on a USD 3.5 billion manufacturing facility in Lehigh Valley, Pennsylvania, as part of its broader USD 50 billion investment to expand medicine production in the US.

Located in Fogelsville, the facility is one of 10 new US manufacturing sites announced by Lilly since 2020. It is one of four sites dedicated to manufacturing injectable medicines and devices.

The new facility will add production capacity for the next generation of obesity treatments, including retatrutide, an investigational, first-in-class triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors.

“Retatrutide is one of several next-generation medicines we’re developing that could help millions more people living with obesity, type 2 diabetes, or both. This USD 3.5 billion investment means we’ll be able to make these medicines in Pennsylvania for people here at home and around the world,” said David A. Ricks, Chair and CEO of Lilly.

Jobs and advanced manufacturing technologies

Lilly is currently hiring for the Lehigh Valley facility, which is expected to create approximately 850 high-wage jobs, including positions for engineers, scientists, operations personnel and laboratory technicians. The project is also expected to generate around 2,000 construction jobs as the site is built and brought online.

According to Lilly, the facility will incorporate state-of-the-art technologies, including machine learning, artificial intelligence (AI), digitally integrated systems and advanced data analytics to improve manufacturing efficiency and support right-first-time execution. Digital automation will be embedded throughout the facility to streamline operations.

Highlighting Lilly’s quality control processes, Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations, said, “Before a dose of medicine leaves one of our sites, each production run goes through more than 5,000 documented steps and each unit is imaged and inspected more than 70 times to check for defects.”

“These are just a few examples of the quality control we take to protect our patients. Lehigh Valley will build on that discipline with next-generation automation and digital systems, so we can do things right the first time and help patients count on their medicines for years to come, made in Pennsylvania,” Hernandez added.

The Lehigh Valley facility is expected to become operational by 2031.

Lilly’s 10 new US manufacturing sites announced since 2020

Lilly’s manufacturing expansion includes 10 sites across three categories:

  • Five active pharmaceutical ingredient (API) manufacturing sites: Richmond, Virginia; Huntsville, Alabama; Houston, Texas; and two facilities in Lebanon, Indiana – Lebanon API and Lilly Medicine Foundry. The latter will also focus on developing new production methods and manufacturing medicines for clinical trials.
  • Four injectable medicines and device manufacturing sites: Research Triangle Park and Concord, North Carolina; Kenosha, Wisconsin; and Lehigh Valley, Pennsylvania.
  • One genetic medicines manufacturing site: Lebanon Advanced Therapies in Lebanon, Indiana.

Last month, Lilly broke ground on a USD 5 billion API manufacturing facility in Goochland County, west of Richmond, Virginia, as part of its planned expansion of five API production sites across the US.

About Us

HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.

Contact: +91 9354115542

HealthXploreIndia @2026. All Rights Reserved.